ACA
ALNY icon

Aptus Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aptus Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
3,389
+1,876
+124% +$566K 0.01% 619
2026
Q1 		$501K Buy
+1,513
New +$515K ﹤0.01% 718

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aptus Capital Advisors's ALNY Position: Q2 2026 in Review

Aptus Capital Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 124% in Q2 2026, buying an estimated $566K and bringing the position to 3,389 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #619.

Aptus Capital Advisors first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Aptus Capital Advisors held 3,389 shares of Alnylam Pharmaceuticals worth $1.02M as of Q2 2026.
  • Aptus Capital Advisors bought 1,876 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $566K.
  • Alnylam Pharmaceuticals made up 0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #619 holding.
  • Aptus Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.